Rivaroxaban is a Small Molecule owned by Bayer, and is involved in 196 clinical trials, of which 163 were completed, 30 are ongoing, and 3 are planned.

Rivaroxaban is a factor Xa inhibitor. The drug candidate blocks factor Xa, an enzyme that is involved in the production of thrombin. Thrombin is central to the process of blood clotting. The activated Factor X (Factor Xa) is a central component of the prothrombinase complex, which converts large amounts of prothrombin (Factor II) to thrombin, described as the “thrombin burst”. By blocking factor Xa, the levels of thrombin decrease, which reduces the risk of blood clots forming in the veins and arteries, and also treats existing clots.

The revenue for Rivaroxaban is expected to reach a total of $29.9bn through 2029. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rivaroxaban NPV Report.

Rivaroxaban is originated and owned by Bayer. Johnson & Johnson is the other company associated in development or marketing of Rivaroxaban.

Rivaroxaban Overview

Rivaroxaban (Xarelto) belongs to the class of antithrombotic agents. It is formulated as film-coated tablets, tablets, granules/powder for suspension and suspension for oral route of administration. Xarelto is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery. Rivaroxaban is indicated for the treatment of adults, to prevent venous thromboembolism (VTE, the formation of clots in the veins) in patients who are undergoing surgery to replace a hip or knee; to prevent stroke caused by a blood clot in the brain and systemic embolism (a blood clot in a blood vessel) in patients with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart); and to treat deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg), and to prevent DVT re-occurring and pulmonary embolism (a clot in a blood vessel supplying the lungs) following a severe case of DVT. Xarelto is also indicated for the treatment of pulmonary thromboembolism and deep vein thrombosis. Xarelto film-coated tablet (2.5 mg), in combination with 75 mg -100 mg acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with symptomatic peripheral artery disease (PAD) at demonstrated high risk of major adverse limb events (MALE) or major adverse cardiovascular and cerebrovascular events (MACCE). Xarelto is indicated for thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who have undergone the Fontan procedure, venous thromboembolism (VTE) and the reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment.

Rivaroxaban (Xarelto) is under development for the treatment of acute venous thromboembolism in pediatric and adult patients, coronary artery disease and high risk of thromboembolic disease in moderate to severe coronavirus disease 2019 (COVID-19).

It was also under development for the prevention of major adverse cardiac events (MACE) in patients with chronic heart failure and significant coronary artery disease, heparin-induced thrombocytopenia (HIT), prevention of stroke in patients who have experienced embolic stroke of undetermined source (ESUS) and myocardial infarction.

Bayer Overview

Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.

The company reported revenues of (Euro) EUR44,081 million for the fiscal year ended December 2021 (FY2021), an increase of 6.5% over FY2020. The operating profit of the company was EUR3,353 million in FY2021, compared to an operating loss of EUR16,169 million in FY2020. The net profit of the company was EUR1,000 million in FY2021, compared to a net loss of EUR10,495 million in FY2020. The company reported revenues of EUR11,281 million for the third quarter ended September 2022, a decrease of 12% over the previous quarter.

Quick View – Rivaroxaban

Report Segments
  • Innovator (NME)
Drug Name
  • Rivaroxaban
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.